Search hospitals > Texas > Fort Worth

Texas Oncology-Fort Worth Cancer Center

Claim this profile
Fort Worth, Texas 76104
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Breast Cancer
Conducts research for Ovarian Tumors
Conducts research for Lung Cancer
98 reported clinical trials
5 medical researchers
Photo of Texas Oncology-Fort Worth Cancer Center in Fort WorthPhoto of Texas Oncology-Fort Worth Cancer Center in Fort WorthPhoto of Texas Oncology-Fort Worth Cancer Center in Fort Worth

Summary

Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Ovarian Tumors, Lung Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 103 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.

Area of expertise

1Cancer
Global Leader
Texas Oncology-Fort Worth Cancer Center has run 20 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
BRCA2 positive
2Ovarian Cancer
Global Leader
Texas Oncology-Fort Worth Cancer Center has run 20 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive

Top PIs

Clinical Trials running at Texas Oncology-Fort Worth Cancer Center

Breast Cancer
Prostate Cancer
Endometrial Cancer
Cancer
Ovarian Cancer
Ovarian Tumors
Pancreatic Cancer
Tumors
Bladder Cancer
Small Cell Lung Cancer
Image of trial facility.

Imlunestrant + Abemaciclib

for Breast Cancer

This study is evaluating whether a drug called LY3484356 can help treat breast cancer.
Recruiting2 awards Phase 39 criteria
Image of trial facility.

Giredestrant + Hormone Therapy

for Early-Stage Breast Cancer

This study is evaluating whether a drug called giredestrant can improve the survival of women with early breast cancer.
Recruiting2 awards Phase 311 criteria
Image of trial facility.

NUV-868 + Olaparib/Enzalutamide

for Cancer

NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b portions include patients with advanced solid tumors and are designed to determine the safety and the dose(s) of NUV-868 to be used as monotherapy and in combination with olaparib or enzalutamide for the Phase 2 portion. In Phase 2, NUV-868 in combination with olaparib or enzalutamide will be given to determine the safety and efficacy of these study treatments. One cohort of patients (with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzalutamide monotherapy, or the combination of NUV-868 + enzalutamide. Patients will self-administer NUV-868 orally daily in 28-day cycles as monotherapy in Phases 1 and 2. In Phases 1b and 2, patients will self-administer NUV-868 orally daily in 28-day cycles in combination with olaparib or enzalutamide daily at standard prescribed doses (Phase 1b) or at the recommended Phase 2 combination dose (RP2cD) that is determined in Phase 1b. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.
Recruiting1 award Phase 1 & 211 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Texas Oncology-Fort Worth Cancer Center?
Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Ovarian Cancer, Breast Cancer, Ovarian Tumors, Lung Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 103 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.